Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2006-05-16
2006-05-16
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C435S009000, C514S090000, C514S151000, C514S183000, C514S245000, C514S449000
Reexamination Certificate
active
07045495
ABSTRACT:
This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.
REFERENCES:
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5728687 (1998-03-01), Bissery et al.
patent: 5821072 (1998-10-01), Schwartz et al.
patent: 6444638 (2002-09-01), Schwartz et al.
Ajani J., et al., Activity of Taxol in Patients with Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus,J. Nat. Canc. Inst. 86(14) :1086-1091 (1994).
Akinaga et al., Enhancement of Antitumor Activity of Mitomycin C In Vitro and In Vivo by UCN-01, a Selective Inhibitor of Protein Kinase C,Cancer Chemother. Pharmacol. 32 (3) :183-189 (1993).
Birchall et al.,J. Pharm. and Exp. Therapeutics, 268 (2) :922-929 (1994).
Foti et al., Proceedings of the American Association for Cancer Research,American Association for Cancer Research, 34:410-411 (1993).
Foti et al., Proceedings of the American Association for Cancer Research,American Association for Cancer Research, 36:11 (1995).
Grant S., et al.,Exp. Cell. Res. 228:65-75 (1996).
Haimovitz-Friedman et al., Protein Kinase C Mediates Basic Fibroblast Growth Factor Protection of Endothelial Cells against Radiation-induced Apoptosis,Cancer Research, 54:2591-2597 (1994).
Hofmann et al., Enhancement of the Antiproliferative Effect of Cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C,Int. J. Cancer, 42:382-388 (1988).
Jarvis et al., Effects of Bryostatin 1 and other Pharmacological Activators of Protein Kinase C on 1-[β-D-Arabinofuranosyl] Cytosine-induced Apoptosis in HL-60 Human Promyelocytic Leukemia Cells,Biochemical Pharmacology, 47 (5) :839-852 (1994).
Kedderis et al.,Fundamental and Applied Toxicology, 25:201-217 (1995).
Kraft et al.,P.N.A.S., 83:1334-1338 (1986).
Lane et al., A Death in the Life of p53,Nature, 362:786-787 (1993).
Losiewicz M.D., et al., Potent inihibition of CDC2 Kinase Activity by the Flavonoid L86-8275,Biopyhs. Biochem. Res. Comm. 201 (2) :589-595 (1994).
Mohammad et al., Bryostatin 1 induces Apoptosis and Augments Inhibitory Effects of Vincristine in Human Diffuse Large Cell Lymphoma,Leukemia Research, 19 (9): 667-673 (1995).
Mohammad et al., Successful Treatment of Human Waldenstrom's Macroglobulinemia with Combination Biological and Chemotherapy Agents,Cancer Research, 54:165-168 (1994).
Ponnathpur et al., Effects of Modulators of Protein Kinases on Taxol-induced Apoptosis of Human Leukemic Cells Possesing Disparate Levels of p26BCL-2 Protein,Clinical Cancer Research, 1:1399-1406 (1995).
Robinson et al., Potentiation of the Antitumor Activity of Doxorubicin by the Protein Kinase C Inhibitor Safingol,Proc. Annu. Meet. Am. Assoc., Cancer Res., 35:A2664 (1994).
Schwartz G., et al., Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.Clinical Cancer Res. 3:1467-1472 (1997).
Schwartz G.K., Protein Kinase C Inhibitors as Inducers of Apoptosis for Cancer Therapy,Exp. Opin. Invest. Drugs, 5(12) : 1601-1615 (1996).
Schwartz et al., Protein Kinase C Activity and Multidrug Resistance in MOLT-3 Human Lymphoblastic Leukemia Cells Resistant to Timetrexate,Cancer Res., 51:55-61 (1991).
Schwartz et al., Potentiation of Apoptosis by Treatment with Protein Kinase C-Specific Inhibitor Safingol in Mitomycin C-Treated Gastric Cancer Cells,Journal of the National Cancer Institute, vol. 87: 1394-1399 (1995).
Wang et al., Apoptosis in 7-Hydroxystauropurine-treated T Lymphoblasts Correlates with Activation of Cyclin-dependent Kinases 1 and 2,Cell Growth and Differentiation, 6:927-936 (1995).
Albino Anthony P.
Schwartz Gary K.
Chong Kimberly
Cooper & Dunham LLP
McGarry Sean
Sloan-Kettering Institute for Cancer Research
White, Esq. John P.
LandOfFree
Combination of bryostatin and paclitaxel for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of bryostatin and paclitaxel for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of bryostatin and paclitaxel for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3620087